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Abstract
Significant advances have been made in
understanding the genetic basis of systemic sclerosis
(scleroderma) in recent years. Can these discoveries
lead to individualized monitoring and treatment?
Besides robustly replicated genetic susceptibility loci,
several genes have been recently linked to various
systemic sclerosis disease manifestations. Furthermore,
inclusion of genetic studies in design and analysis of
drug trials could lead to development of genetic
biomarkers that predict treatment response. Future
genetic studies in well-characterized systemic sclerosis
cohorts paired with advanced analytic approaches can
lead to development of genetic biomarkers for
targeted diagnostic and therapeutic interventions in
systemic sclerosis.
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Background
Systemic sclerosis (SSc or scleroderma) is a multisystem,
uncommon disease characterized by fibrosis in skin and
internal organs, immune dysregulation, and vasculopathy.
Its pathogenesis remains poorly understood but there is a
growing body of evidence implicating in part genetic fac-
tors. However, the genetic basis for SSc is defined by
multiple genes that have only modest effect on disease
susceptibility [1,2]. Moreover, the disease is thought to
arise from an interaction between genetic factors and
environmental triggers.
SSc is subdivided into limited and diffuse types based
on the extent of skin involvement [3]. Furthermore, SSc
can be sub-grouped based on the presence of non-over-
lapping autoantibodies that are associated with various
disease manifestations [4]. The standardized mortality
ratio of patients with SSc is 3.5 [5] which is higher than
most other rheumatic diseases. Reliable predictors of dis-
ease course and therapeutic options are very limited.
Genetic data are not time-dependent and do not change
over the course of disease; thus they are attractive candi-
dates for development of predictive biomarkers. In this
review, we will examine the implication of recent discov-
eries in SSc genetics for drug development and identifica-
tion of predictive biomarkers.
Recent advances in SSc genetics
Case-control candidate gene studies have identified several
robust SSc susceptibility loci that have been confirmed in
subsequent independent studies (reviewed in [1,2]). The
majority of these genes such as IRF5 [6], STAT4 [7],
BANK1 [8] and BLK [9] belong to pathways involved in
immune regulation. Furthermore, three genome wide
association studies (GWAS) allowed unbiased genetic pro-
filing of patients with SSc [10-12]. These studies have con-
firmed genes in the major histocompatibility complex
(MHC) as the strongest susceptibility loci. Furthermore, a
GWAS follow-up study confirmed that HLA-DQB1, HLA-
DPA1/B1, and NOTCH4 associations with SSc are likely
confined to SSc specific auto-antibodies [13].
Multiple non-MHC susceptibility loci also have been
identified in the above-mentioned studies. As shown in
Table 1, the most robust associations are in genes related
to innate immunity, as well as B- and T-cell activation.
For example, IRF5 belongs to a family of transcription fac-
tors in the type I interferon pathway which is an important
component of the innate immunity, whereas CD247
encodes the T-cell receptor zeta subunit modulating T-
cell activation. The majority of these gene variants are also
risk loci for other autoimmune diseases, especially for sys-
temic lupus erythematosus (SLE) [2,14]. This indicates
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that SSc has a shared immune pathogenesis with other
autoimmune diseases providing further support for the
concept of quantitative thresholds in immune-cell signal-
ing. In this concept, several genetic factors of relatively
small effect may cumulatively create a state of susceptibil-
ity to autoimmune diseases (reviewed in [15]). Self-reactive
B and T-cells are a normal component of the immune sys-
tem. However, they are usually kept in check by regulatory
mechanisms in the thymus/bone marrow or peripheral
blood. In the concept of quantitative threshold, the impli-
cated genetic variations lead cumulatively to an impair-
ment of necessary biological processes for destruction of
self-reactive immune cells and regulating auto-reactivity.
Validity of this concept in SSc is supported by the fact that
several SSc genetic susceptibility loci overlap not only with
SLE but also with other autoimmune diseases. For exam-
ple, STAT4 is also implicated in rheumatoid arthritis [16],
and primary biliary cirrhosis [17]. Similarly, PTPN22 is a
susceptibility locus in rheumatoid arthritis [18], type 1 dia-
betes mellitus [19], and also SSc [20].
Some of the confirmed SSc susceptibility loci show a
stronger association with its serological or clinical (limited
versus diffuse) [13] subtypes than the overall disease. Sev-
eral genetic associations in the HLA [8,21] or non-HLA
regions, such as BANK1, IRF8, SOX5 and IRF7 are mainly
with the SSc-related autoantibodies (e.g. anti-centromere
or anti-topoisomerase I) or clinical subtypes of disease
[1,2,8,22]. Furthermore, many of the identified single
nucleotide polymorphisms (SNPs) are merely a tag genetic
variant for the yet to be identified causal allele. This is also
applicable to GWA studies, because the utilized platforms
provide more than 80% coverage for common polymorph-
isms in human genome by investigating SNPs that are in
strong linkage disequilibrium with multiple other SNPs
and serve as proxies for gene areas. Advances in gene
sequencing techniques will permit large scale sequencing
of these susceptibility genes to pinpoint the actual causal
variant.
Some of the reported genetic associations in one ethnic
group might not replicate in other ethnicities. The
reported polymorphisms might not tag the causal locus
in all ethnic groups because of the varying linkage dise-
quilibrium structure among different ethnicities. Alterna-
tively, the reported genetic associations might be truly an
ethnic specific susceptibility locus for SSc.
It is noteworthy that the gene variants of interest do
not operate in isolation as they are parts of intertwined
biological pathways. Therefore, examination of gene-
gene or gene-environment interactions can lead to bet-
ter understanding of SSc pathogenesis. Lastly, mechanis-
tic studies are needed to elucidate how these immune
system gene variants contribute to the cross-talk among
immune, vascular and fibrotic pathways leading to the
unique phenotype of SSc.
Implication of SSc genetics for predicting disease severity
and organ involvement
SSc is associated with high morbidity and mortality. The
disease related mortality is mainly driven by internal organ
involvement [23], especially severity of lung disease
[24,25]. As shown in Table 2, several studies have also
investigated the association of MHC and non-MHC
genetic loci with interstitial lung disease (ILD), pulmonary
arterial hypertension (PAH), scleroderma renal crisis, and
mortality. It is important to point out that the comparison
of SSc patients with a particular disease manifestation with
patients without that particular organ involvement (case-
case analysis) is more relevant for biomarker development
than comparison of patient with the disease manifestation
to unaffected controls (case-control analysis). The main
reason for this notion is that the prognostic biomarkers
are useful if they can aid clinicians to subgroup patients
(cases-case analysis) based on the expected disease pro-
gression. A case to control comparison does not occur
in the clinical settings because the diagnosis of SSc is
already established before clinicians become interested in
Table 1 Selected non-major histocompatibility complex susceptibility genes for systemic sclerosis which were
confirmed in at least two independent studies.
Approximate OR Potential Function
BANK1 1.2-1.5* Lymphocyte activation - B cells
BLK 1.2-1.5 Lymphocyte activation - B cells
CD247 1.2-1.5* Lymphocyte activation - T cells
CD226 1.0-1.2 Lymphocyte activation - T cells
IRF5 1.2-1.5 Innate immune signaling - Interferon pathway
MIF 1.0-1.2 Adhesion molecule on endothelial cells
PTPN22 1.2-1.5 Lymphocyte activation - T cells
STAT4 1.2-1.5 Innate immune signaling and lymphocyte activation - T cells
TNFSF4 1.2-1.5 Lymphocyte activation - T cells and B cells
*The minor allele is protective. The inverse ratio OR is reported.
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predicting the disease course. IRF5 gene variants have
been linked to overall mortality independent of disease
type and serology [26]. CTGF [27], HGF [28], IRAK1 [29],
IRF5 [6,26,30], MMP-12 [31], SP-B [32] polymorphisms
are reported to be associated with ILD. The case definition
for ILD varies considerably, some investigators have relied
on the presence of reticular or ground glass opacities on
high resolution chest computer tomography (HRCT)
while others have focused on severity of ILD based on the
pulmonary function results. The former approach does
not differentiate between the mild stable ILD and its
severe progressive forms. Furthermore, IL23R [33],
KCNA5 [34], TLR2 [35], TNAIP3 [36], and UPAR [37]
genes are reported to be associated with PAH while HLA-
DRB1*04:07 and *13:04 were associated with scleroderma
renal crisis [38].
However, the above findings need to be replicated in
independent studies. Furthermore, the currently avail-
able cross-sectional patient populations for SSc genetic
studies are most likely affected by survival bias, i.e. the
examined prevalent cohorts with longstanding disease
are depleted of patients with the most progressive and
severe form of SSc. For example, SSc patients with
rapidly progressive ILD have a higher mortality [39],
therefore patient samples with long-standing disease
(mean disease duration > 5 years) are depleted of the
most severe form of ILD. This can lead to decreased fre-
quency of genetic loci associated with more severe
forms of disease in the investigated patient samples.
Examination of incident cases with longitudinal follow-
up can avoid problems arising from survival bias.
Furthermore, the genetic severity loci might be different
than the genes linked to SSc susceptibility. For example,
HGF was not a susceptibility locus for SSc but was asso-
ciated with end-stage lung disease among Japanese SSc
patients [28]. A careful phenotypic characterization of
patients examined in GWAS can permit an unbiased
profiling of severity loci. This will also allow combina-
tion of genetic data with other clinical and serological
markers of disease severity for risk prediction.
Risk prediction in genetically complex diseases like
SSc requires statistical approaches that extend beyond
separate odds ratios for each SNP of interest. Genotypes
at multiple SNPs can be combined into cumulative
scores calculated according to the number of severity
alleles carried. Furthermore, risk reclassification statistics
can be used to combine genetic and clinical data. In this
approach, patients in the intermediate risk group based
on clinical data are reassigned to low- or high-risk cate-
gories using the pertinent genetic information.
Implication of SSc genetics for treatment selection
The newly identified genetic susceptibility pathways can
lead to identification of novel therapeutic targets and
guide drug development. Indeed, some of the currently
investigated biologic therapies for SSc match appropri-
ately to these pathways. These include anti-interferon (e.
g. sifalimumab) and anti-B-cell agents (e.g. rituximab)
[40]. Furthermore, the SSc genetic data lend support to
T-cell directed therapies (e.g. abatacept). However, there
are no reported large-scale, randomized controlled stu-
dies of B-cell, T-cell, interferon directed therapies in
patients with SSc.
Beyond identification of new therapeutic targets, the
genetic information might be used to identify the high
responsive group to a particular biologic treatment.
There are no data on predictive significance of genetic
information for response to treatment in SSc. This
requires the collection of genetic material in drug trials
and careful analysis of genetic information conditional
on the study outcomes. Considering the modest effect
of these gene variants on the disease susceptibility, we
might be underpowered to examine the predictive sig-
nificance of these factors in drug trials using traditional
(frequentist) statistical methods (especially after sample
partitioning into treatment and control arms). Bayesian
analysis of trial results in uncommon diseases such as
SSc [41] might lead to more flexible and clinically useful
biomarker development.
Independent of disease susceptibility genes, the genetic
information can be used to predict drug metabolism and
development of adverse effects (pharmacogenetics). For
example, polymorphism in the UGT1A9 affect metabo-
lism of mycophenolate mofetil and predict acute rejec-
tion in renal transplant patients [42,43]. Despite the
widespread use of mycophenolate mofetil, the role of
this polymorphism for response to treatment and
Table 2 Selected genes associated with various SSc
disease manifestations based on case- case comparisons.
Gene Clinical Association
CTGF ILD by pulmonary function test or HRCT [27]
HGF End-stage ILD by pulmonary function test [28]
HLA-
DRB1*04:07
Scleroderma Renal Crisis [38]
HLA-
DRB1*13:04
Scleroderma Renal Crisis [38]
IL23R PAH by echocardiogram or right heart catheterization
[33]
IRAK1 ILD by HRCT [29]
IRF5 Overall survival [26]
ILD by HRCT [6,30]
Severity of ILD by pulmonary function test [26]
KCNA5 PAH by right heart catheterization [34]
MMP-12 ILD by pulmonary function test and HRCT [31]
SP-B ILD by HRCT [32]
TLR2 PAH by right heart catheterization [35]
TNFAIP3 PAH by right heart catheterization [36]
UPAR PAH by right heart catheterization [37]
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development of adverse events has not been investigated
in SSc patients.
In a recently published study, a polymorphism in the
IL-6 gene predicted response to rituximab in a sample
of patients with SLE and other rheumatic diseases that
included patients with SSc [44].
Conclusion
The significant advances in SSc genetics represent an
opportunity for biomarker development. Careful phenoty-
pic characterization, independent confirmation of current
findings, inclusion of genetic studies in drug trials, and uti-
lization of novel analytic approaches paired with advanced
high-throughput technologies can potentially lead to iden-
tification of genetic markers that predict disease severity
and response to treatment in SSc.
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